The status of BCL‐2 in this group relative to EBV‐negative cases is still debated, probably because overexpression of BCL‐2 is frequently observed in DLBCL due to genetic mechanisms. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.